Evidence map›Paper›PMID 37648907›Full record

ArticleJournal of endocrinological investigation2024

Cardiovascular evaluation and endothelial dysfunction in Cushing syndrome following remission: a prospective study.

A Hacioglu, S T Firat, A S Caglar, Z Karaca, N Kalay, S Taheri, F Tanriverdi, A Selcuklu, K Unluhizarci, F Kelestimur

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Hypercoagulable state and risk of venous thromboembolism in Cushing syndrome.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A HaciogluDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
S T FiratDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
A S CaglarDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
Z KaracaDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey. zuleyha@erciyes.edu.tr.ORCID http://orcid.org/0000-0003-3241-2352
N KalayDepartment of Cardiology, Erciyes University Medical School, Kayseri, Turkey.
S TaheriDepartment of Medical Biology, Erciyes University Medical School, Kayseri, Turkey.
F TanriverdiDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
A SelcukluDepartment of Neurosurgery, Erciyes University Medical School, Kayseri, Turkey.
K UnluhizarciDepartment of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
F KelestimurFaculty of Medicine, Department of Endocrinology, Yeditepe University, Istanbul, Turkey.
Erciyes University · TRYeditepe University · TR

Funding

Bilimsel Araştırma Projeleri, Erciyes Üniversitesi TTU-2013-4566
6 · The paper itself

Abstract

purposeCushing syndrome (CS) is a well-known risk factor for cardiovascular morbidities. We aimed to evaluate endothelial and cardiovascular functions, endothelial mediators and pro-inflammatory cytokines in patients with CS before and after remission.

methodsAdult patients with newly diagnosed endogenous CS were included. Metabolic [body mass index (BMI), glucose, and lipid values] and cardiovascular evaluation studies [24-h ambulatory blood pressure monitoring, carotid intima-media thickness (CIMT), flow-mediated dilation (FMD), and echocardiography] were performed, and endothelial mediators [asymmetric dimethyl arginine (ADMA) and endothelin-1 (ET-1)] and pro-inflammatory cytokines [interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α)] were measured. Control group was matched in terms of age, gender, and BMIs.

resultsTwenty-five patients, mean age 40.60 ± 14.04 years, completed the study. Compared to controls (n = 20) mean arterial pressure (MAP) and CIMT were higher (p < 0.005 and p = 0.012, respectively), and FMD (p < 0.001) and mitral E/A ratio (p = 0.007) lower in the patients during active disease. Baseline serum ADMA, ET-1, and IL-1β were similar between the groups, while TNF-α was lower in the patients (p = 0.030). All patients were in complete remission 1 year following surgery. BMI, LDL cholesterol, serum total cholesterol, fasting plasma glucose, MAPs, and CIMT significantly decreased (p < 0.005), while there was no improvement in FMD (p = 0.11) following remission. There was no significant change in ADMA, IL-1β, and TNF-α levels, but ET-1 increased (p = 0.011).

conclusionsRemission in CS improves some cardiovascular parameters. ADMA and ET-1 are not reliable markers for endothelial dysfunction in CS. Metabolic improvements may not directly reflect on serum concentrations of TNF-α and IL-1β following remission of CS.

Indexed as

Cushing SyndromeVascular DiseasesAdultBlood Pressure Monitoring, AmbulatoryCarotid Intima-Media ThicknessCytokinesHumansMiddle AgedProspective StudiesTumor Necrosis Factor-alphaCytokinesTumor Necrosis Factor-alphaCushing syndromeEndothelin-1Interleukin-1Tumor necrosis factor-alpha

Identifiers

PMID37648907
OpenAlexW4386287284

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.